SKAN Group Past Earnings Performance
Past criteria checks 3/6
SKAN Group has been growing earnings at an average annual rate of 24.4%, while the Life Sciences industry saw earnings growing at 12.3% annually. Revenues have been growing at an average rate of 32.4% per year. SKAN Group's return on equity is 18.9%, and it has net margins of 9.4%.
Key information
24.4%
Earnings growth rate
-0.5%
EPS growth rate
Life Sciences Industry Growth | 17.6% |
Revenue growth rate | 32.4% |
Return on equity | 18.9% |
Net Margin | 9.4% |
Next Earnings Update | 25 Mar 2025 |
Recent past performance updates
Recent updates
Should You Investigate SKAN Group AG (VTX:SKAN) At CHF77.10?
Oct 08A Look At The Intrinsic Value Of SKAN Group AG (VTX:SKAN)
Jul 27Is SKAN Group AG (VTX:SKAN) Potentially Undervalued?
Jun 19SKAN Group AG's (VTX:SKAN) P/E Is On The Mark
May 30Do SKAN Group's (VTX:SKAN) Earnings Warrant Your Attention?
May 14We Take A Look At Why SKAN Group AG's (VTX:SKAN) CEO Has Earned Their Pay Packet
May 01Is There An Opportunity With SKAN Group AG's (VTX:SKAN) 27% Undervaluation?
Apr 19We Think That There Are Issues Underlying SKAN Group's (VTX:SKAN) Earnings
Apr 03SKAN Group AG Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Mar 29When Should You Buy SKAN Group AG (VTX:SKAN)?
Mar 11SKAN Group AG's (VTX:SKAN) Earnings Haven't Escaped The Attention Of Investors
Jan 26Estimating The Fair Value Of SKAN Group AG (VTX:SKAN)
Dec 21Is There Now An Opportunity In SKAN Group AG (VTX:SKAN)?
Nov 22A Look At The Fair Value Of SKAN Group AG (VTX:SKAN)
Sep 21How Much Of BV Holding AG (BRN:BVHN) Do Insiders Own?
Mar 11Here's Why I Think BV Holding (BRN:BVHN) Is An Interesting Stock
Feb 04Did You Participate In Any Of BV Holding's (BRN:BVHN) Fantastic 204% Return ?
Dec 31How Much Of BV Holding AG (BRN:BVHN) Do Insiders Own?
Dec 03Revenue & Expenses Breakdown
How SKAN Group makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Jun 24 | 344 | 32 | 169 | 0 |
31 Mar 24 | 332 | 29 | 164 | 0 |
31 Dec 23 | 320 | 26 | 159 | 0 |
30 Sep 23 | 308 | 27 | 152 | 0 |
30 Jun 23 | 296 | 27 | 145 | 0 |
31 Mar 23 | 286 | 23 | 140 | 0 |
31 Dec 22 | 277 | 19 | 135 | 0 |
30 Sep 22 | 265 | 13 | 129 | 0 |
30 Jun 22 | 253 | 7 | 124 | 0 |
31 Mar 22 | 244 | 9 | 119 | 0 |
31 Dec 21 | 234 | 11 | 115 | 0 |
30 Sep 21 | 217 | 7 | 110 | 0 |
30 Jun 21 | 200 | 3 | 105 | 0 |
31 Mar 21 | 196 | 4 | 101 | 0 |
31 Dec 20 | 192 | 5 | 97 | 0 |
30 Sep 20 | 150 | 12 | 71 | 0 |
30 Jun 20 | 109 | 20 | 45 | 0 |
31 Mar 20 | 64 | 19 | 23 | 0 |
31 Dec 19 | 19 | 18 | 1 | 0 |
30 Sep 19 | 13 | 12 | 1 | 0 |
30 Jun 19 | 7 | 6 | 1 | 0 |
31 Mar 19 | 7 | 6 | 1 | 0 |
31 Dec 18 | 7 | 6 | 1 | 0 |
30 Sep 18 | 11 | 8 | 1 | 0 |
30 Jun 18 | 14 | 9 | 1 | 0 |
31 Mar 18 | 17 | 12 | 1 | 0 |
31 Dec 17 | 20 | 15 | 1 | 0 |
30 Sep 17 | 17 | 13 | 1 | 0 |
30 Jun 17 | 15 | 10 | 1 | 0 |
31 Mar 17 | 19 | 13 | 1 | 0 |
31 Dec 16 | 24 | 16 | 1 | 0 |
30 Sep 16 | 23 | 15 | 1 | 0 |
30 Jun 16 | 21 | 14 | 1 | 0 |
31 Mar 16 | 22 | 16 | 1 | 0 |
31 Dec 15 | 23 | 18 | 1 | 0 |
30 Sep 15 | 22 | 19 | 1 | 0 |
30 Jun 15 | 21 | 19 | 2 | 0 |
31 Mar 15 | 13 | 12 | 1 | 0 |
31 Dec 14 | 6 | 4 | 1 | 0 |
30 Sep 14 | 6 | 5 | 1 | 0 |
30 Jun 14 | 6 | 5 | 1 | 0 |
31 Mar 14 | 4 | 4 | 1 | 0 |
31 Dec 13 | 3 | 2 | 1 | 0 |
Quality Earnings: SKAN has a high level of non-cash earnings.
Growing Profit Margin: SKAN's current net profit margins (9.4%) are higher than last year (9.2%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: SKAN's earnings have grown significantly by 24.4% per year over the past 5 years.
Accelerating Growth: SKAN's earnings growth over the past year (17.9%) is below its 5-year average (24.4% per year).
Earnings vs Industry: SKAN earnings growth over the past year (17.9%) exceeded the Life Sciences industry 4.3%.
Return on Equity
High ROE: SKAN's Return on Equity (18.9%) is considered low.